Terms: = Germ cell tumor AND GNA11, GNA-11, 2767, ENSG00000088256 AND Treatment
84 results:
1. Identification and validation of a costimulatory molecule-related signature to predict the prognosis for uveal melanoma patients.
Zhao M; Yu Y; Song Z
Sci Rep; 2024 Apr; 14(1):9146. PubMed ID: 38644411
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
3. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the treatment of Metastatic Uveal Melanoma.
Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
[TBL] [Abstract] [Full Text] [Related]
5. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract] [Full Text] [Related]
6. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract] [Full Text] [Related]
7. Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
Pigné T; Lévy M; Ducharme O; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Prey S
Melanoma Res; 2023 Jun; 33(3):252-256. PubMed ID: 36919691
[TBL] [Abstract] [Full Text] [Related]
8. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Xu B; Sun T; Shi Y; Cui J; Yin Y; Ouyang Q; Liu Q; Zhang Q; Chen Y; Wang S; Wang X; Tong Z; Zhong Y; Wang J; Yan M; Yan X; Wang C; Feng J; Wang X; Hu G; Cheng Y; Ge R; Zhu Z; Zhang W; Shao Z
Breast Cancer Res Treat; 2023 Feb; 197(3):489-501. PubMed ID: 36459284
[TBL] [Abstract] [Full Text] [Related]
9. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract] [Full Text] [Related]
10. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract] [Full Text] [Related]
11. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in cell Line Models of Uveal Melanoma.
Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
[TBL] [Abstract] [Full Text] [Related]
12. Primary sellar melanocytoma.
Claus M; Van Der Linden M; Van Dorpe J; Lapauw B; T'Sjoen G
Pituitary; 2021 Dec; 24(6):970-977. PubMed ID: 34518998
[TBL] [Abstract] [Full Text] [Related]
13. Bioinformatics analysis of GNAQ, gna11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract] [Full Text] [Related]
14. A challenging case of sporadic melanocytoma of the jugular foramen.
Donofrio CA; Roncaroli F; Riccio L; Pereira M; O'Sullivan J; Mayers H; Potter GM; Djoukhadar I; Rutherford SA
Neurochirurgie; 2022 Jul; 68(4):453-457. PubMed ID: 34157339
[TBL] [Abstract] [Full Text] [Related]
15. Primary leptomeningeal melanoma: the prognostic significance of its genetic signature and embryological origin.
Buckland A; Green C; Kho LK; Prentice D
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34031065
[TBL] [Abstract] [Full Text] [Related]
16. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ
Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548
[TBL] [Abstract] [Full Text] [Related]
17. Development of new therapeutic options for the treatment of uveal melanoma.
Wang JZ; Lin V; Toumi E; Wang K; Zhu H; Conway RM; Madigan MC; Murray M; Cherepanoff S; Zhou F; Shu W
FEBS J; 2021 Nov; 288(21):6226-6249. PubMed ID: 33838075
[TBL] [Abstract] [Full Text] [Related]
18. Current molecular and clinical insights into uveal melanoma (Review).
Fallico M; Raciti G; Longo A; Reibaldi M; Bonfiglio V; Russo A; Caltabiano R; Gattuso G; Falzone L; Avitabile T
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649778
[TBL] [Abstract] [Full Text] [Related]
19. Uveal melanoma: laboratory advances and new frontiers in patient care.
Xu TT; Moser JC; Dalvin LA
Curr Opin Ophthalmol; 2021 May; 32(3):301-308. PubMed ID: 33606406
[TBL] [Abstract] [Full Text] [Related]
20. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract] [Full Text] [Related]
[Next]
